Resources
52 Results (showing 1 - 10)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 5/26/2021 (updated 4/10/2024)
Posted 5/26/2021 (updated 4/10/2024)
Opioid dependence is a chronic relapsing disorder with considerable individual and global public health burden. The current standard of care for opioid dependence includes treatment with methadone or sublingual (SL) buprenorphine or buprenorphine-naloxone (hereafter, buprenorphine), combined with psychosocial and behavioral support. Both medications are associated with reductions in mortality, illicit opioid use, bloodborne viral infections, and criminal behavior as well as better cost-effectiveness than no treatment or psychosocial treatment alone. Buprenorphine is a partial μ-opioid receptor agonist, enabling office-based treatment for nonsupervised or take-home use of the medication. However, SL formulations of buprenorphine are prone to nonmedical use (eg, injecting, diversion), prompting models of care, particularly in the early phases of treatment, requiring regular attendance at clinics or pharmacies for administration of doses.
Posted 5/17/2021 (updated 4/10/2024)
FAQs About the New Buprenorphine Practice Guidelines
Buprenorphine Quick Start Guide
Buprenorphine Waiver Notification
Posted 4/21/2021 (updated 4/5/2024)
This News Brief defines psychostimulants; explains why psychostimulant use disorder is under-addressed, particularly in rural areas; reviews the reasons why people use psychostimulants and the harms they can cause; and addresses the impact of COVID-19 on psychostimulant use.
Posted 4/1/2021 (updated 4/5/2024)
This webinar will provide an overview of COVID-19 impacts and vaccination attitudes among SUD populations in Vermont including people who use drugs, patients receiving MAT, and people in recovery. It will outline the methods undertaken to conduct a community-based survey. It will discuss the barriers and opportunities that arose from analysis of the survey and a subsequent consortium workshop.
Posted 3/25/2021 (updated 4/5/2024)
Stimulants 2021: An Update—Clinical Issues and Treatments
The presenter will review considerations in engaging and treating individuals with stimulant use disorders and present evidence-based treatment strategies relevant to rural communities addressing this growing problem.
Posted 3/25/2021 (updated 4/5/2024)
Integrating Health Promotion for People Who Inject Drugs (PWID) Into Opioid Use Disorder (OUD) Services
The workshop will present strategies to integrate HIV, hepatitis, and sexual health concerns into services for PWID. The session will focus on communication skills, assessment techniques, and building motivation among PWID to make healthier choices. The presenter will look at programmatic and clinical-level integration strategies and offer participants an opportunity to assess current service delivery models and develop a plan to enhance care.
Posted 2/18/2021 (updated 4/4/2024)
Opioid use disorder (OUD), a chronic disease, is a major public health problem. Despite availability of effective treatment, too few people receive it and treatment retention is low. Understanding barriers and facilitators of treatment access and retention is needed to improve outcomes for people with OUD.
In this study we sought to assess 3-month outcomes from a patient-centered practice that included MAT with buprenorphine or naltrexone plus the option to participate in psychosocial treatments. The psychosocial treatments included case management, psychotherapy, peer recovery groups such as Narcotics Anonymous or Smart Recovery, or peer support through a local harm reduction program.
Posted 2/17/2021 (updated 4/4/2024)
People suffering from addiction or people who are in recovery from the condition, face a variety of challenges, including, in many cases, in their interactions with health-care services. Many of these challenges may be attributed to the stigma that still clings unhelpfully to addiction. It may also be due to a surprising lack of awareness even among health-care professionals about the nature of addiction and the susceptibilities and anxieties of those initiating or attempting to sustain recovery.
This review and report is a starting point, an attempt to get a handle on the state of play and the issues that need addressing when it comes to pain management in people with current or past addictions. It helps to identify gaps in knowledge, understanding, skill, practice and culture, pointing the way to how these deficiencies might be remedied.
Posted 12/29/2020 (updated 4/4/2024)
Whereas outpatient treatment with medication for opioid use disorder (MOUD) is evidence based, there is a large network of inpatient facilities in the US that are reimbursed by commercial insurers and do not typically offer MOUD. This study is a comparison of rates of overdose and hospitalization after initiation of medication for Opioid Use Disorder in the inpatient vs outpatient setting.